6-aminonicotinamide has been researched along with malondialdehyde in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hidalgo, J; Penkowa, M | 1 |
| Camats, J; Campbell, IL; Giralt, M; Hadberg, H; Hidalgo, J; Molinero, A; Penkowa, M; Quintana, A; Rojas, S | 1 |
2 other study(ies) available for 6-aminonicotinamide and malondialdehyde
| Article | Year |
|---|---|
IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment.
Topics: 6-Aminonicotinamide; Animals; Antigens, Differentiation; Astrocytes; Blood-Brain Barrier; Bone Marrow Cells; Brain Stem; Encephalitis; Glial Fibrillary Acidic Protein; Hematopoiesis; Immunohistochemistry; Interleukin-6; Macrophages; Malondialdehyde; Metallothionein; Metallothionein 3; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Nerve Tissue Proteins; Oxidative Stress; Protein Isoforms; Serum Albumin; T-Lymphocytes; Tyrosine | 2000 |
Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide.
Topics: 6-Aminonicotinamide; Angiogenesis Inducing Agents; Animals; Apoptosis; Astrocytes; Brain Stem; Cell Count; Central Nervous System; Cytokines; Disease Models, Animal; Gene Targeting; Glial Fibrillary Acidic Protein; Growth Substances; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-6; Lymphocytes; Macrophages; Malondialdehyde; Metallothionein; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Nerve Degeneration; Oxidative Stress; Staining and Labeling; Stem Cells; Teratogens; Tyrosine | 2003 |